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BRIEF REVIEWS 
Gene Transfer and 
Cardiovascular Disease 
Elizabeth G. Nabel and Gary J. Nabel 
Through the introduction of foreign DNA into somatic cells, the aim of 
gene therapy is to correct or prevent disorders caused by the absence or 
malfunction of genes within a diseased individual. Expression of 
recombinant genes at specific sites within the vasculature can provide 
insights into vascular biology and potential treatments for various 
cardiovascular disorders. In our studies, we have developed methods 
for the transfer of recombinant genes into the endothelium and vascular 
smooth muscle cells by using retroviral vectors and liposomal 
transfection. Although these techniques are still in the formative stages, 
gene transfer into the endothelium and other vascular cells is a new 
approach to the treatment of vascular diseases, including atherosclero- 
sis and restenosis. 
Advances in recombinant DNA technol- 
ogy have resulted in the production of 
biologic products that can be applied to 
clinical medicine for diagnostic and ther- 
apeutic purposes. Over the past decade, 
the potential of gene therapy as a treat- 
ment modality for inherited and ac- 
quired disorders has emerged. This tech- 
nology involves the insertion of normal 
genes into the somatic cells of patients to 
correct an inherited or acquired disorder 
through the synthesis of missing or 
defective gene products in vivo (Ander- 
son 1984; Belmont and Caskey 1986). A 
variety of approaches to human gene 
transfer are currently under experimen- 
tal investigation (reviewed by Friedmann 
1989). A protocol to treat people who 
have adenosine deaminase deficiency 
has recently begun at the National Insti- 
tutes of Health, but gene therapy is still 
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in a formative stage and has not yet 
successfully treated human disease. Sev- 
eral gene transfer protocols, which use 
recombinant genes as markers to study 
disease, are also in progress. 
Various mechanical, chemical, and 
viral methods have been employed to 
introduce recombinant genes into host 
cells of different organ systems. These 
include the bone marrow (Hock and 
Miller 1986; Lemischka et al. 1986), liver 
(Wilson et al. 1988a and b), lymphocytes 
(Belldegrun et al. 1989), central nervous 
system (Palella et al. i988), and lung 
(Garver et al. 1987a and b). This review 
focuses on attempts to target gene modi- 
fication to cardiovascular disorders, par- 
ticularly diseases of the vasculature. 
l Gene Transfer Approaches 
To successfully deliver DNA to host cells, 
a gene transfer system must meet several 
requirements, including (a) high effi- 
ciency of transmission: (b) stable repli- 
cation of the foreign DNA, either as an 
integrated transgene or as an extrachro- 
mosomal element; (c) appropriate and 
regulated expression in the target tissue: 
and (d) adequate safety over the time of 
transfer and the life of the host. 
To correct a missing or defective gene, A variety of techniques have been used 
three methods can be used: gene replace- in the laboratory to introduce genes into 
ment, gene correction, and gene aug- cells in tissue culture. Physical methods 
mentation. Gene replacement requires for the introduction of DNA into cells 
the specific removal of a mutant gene include microinjection and electropora- 
sequence from the host genome and its tion. Microinjection of plasmid DNA 
replacement with a normal, functional into a host cell can be achieved by using 
gene. Partial gene replacement with gene 
targeting has been accomplished suc- 
cessfully in the laboratory, but it is 
impractical for human gene therapy 
owing to many technical difficulties. 
Gene correction attempts to alter the 
defective portion of a mutant gene and 
makes the gene functional without chang- 
ing the gene to a natural form. Although 
gene correction is technically possible, it 
is still difficult to perform. Recently, 
genetic targeting of foreign sequences 
leading to specific gene sequence modifi- 
cation has been accomplished in several 
mammalian systems in tissue culture 
(Doethschman et al. 1987; Mansour et al. 
1988). 
Gene augmentation is a more estab- 
lished technique for modifying the ex- 
pression of mutant genes in defective 
cells by introducing foreign normal ge- 
netic sequences into the host genome and 
leaving the host genes unaltered. Using 
this technique, it is possible to restore 
genetic function by the introduction of 
functional genes into nonspecific sites in 
the host genome without removal of the 
nonfunctional, mutant gene. Although 
mutational events could arise from the 
integration of foreign sequences at ec- 
topic sites in the genome, this complica- 
tion has not yet arisen in practice. For 
this reason, gene augmentation has re- 
ceived considerable attention. 
9 Physical and Chemical Methods of 
Gene Transfer 
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Figure 1. Construction of a retroviral vector. The foreign genes are inserted into the defective 
viral plasmid (BAG vector). A packaging helper cell line is made with a separate plasmid 
containing the gag, pol, and env genes and then transfected with the cloned BAG retroviral 
vector. The resulting retrovirai vector virus is released into the culture media. From Nabel(l989). 
a special apparatus under microscopic 
control (Anderson et al. 1980). Although 
it is reasonably efficient, its major disad- 
vantage is that only one cell can be 
injected at a time and transfection of a 
large number of cells is not feasible. An 
alternative physical approach, electropo- 
ration, is the transport of DNA into the 
cell by disrupting the surface membrane 
with a rapid pulse of high-voltage cur- 
rent (Neumann et al. 1982). 
Exogenous DNA can also be intro- 
duced into cells by chemical methods, 
including coprecipitation with calcium 
phosphate, polycations or lipids to com- 
plex with DNA, and encapsidation of 
DNA into liposomes (Felgner et al. 1987). 
A general characteristic of most of these 
transfection methods is the integration 
of multiple repeated copies of the foreign 
gene into the genome in a relatively 
stable form. These methods are investi- 
gational and have not been used in 
clinical protocols. 
l Viral Vectors 
Viral vectors are a more efficient delivery 
system for introducing genes into host 
cells than physical or chemical methods. 
A variety of viruses now have been 
employed as vectors, including adeno- 
virus (Morin 1987) retrovirus (Varmus 
1988), and DNA viruses (Palella 1989). 
Retroviruses offer advantages and disad- 
vantages as a gene-delivery system. Their 
genetic structure is well characterized. 
Many viruses are amphotropic; that is, 
they can infect a variety of cell types 
from different species. Retroviruses pro- 
duce efficient infection of the host cell, 
followed by integration of the foreign 
gene into the host cell. However, there 
are several important safety issues that 
must be addressed before viral vectors 
can be used on a routine clinical basis. 
Most important is the need to demon- 
strate that the retrovirus cannot replicate 
ad hoc in the host cell or form wild-type 
recombinants that could replicate in an 
unregulated manner. These potential com- 
plications can be minimized by altering 
the viral genome to render the virus 
replication defective. 
Most retroviral vectors used in experi- 
mental studies are derived from am- 
photropic murine or avian retroviruses. 
A viral vector is constructed by first 
deleting the structural genes required for 
viral replication (gag, pol, and env genes) 
from the retroviral genome (Cepko et al. 
1984), but retaining a sequence required 
for viral packaging. Foreign DNA is 
ligated into the deleted genome of the 
retrovirus. This retroviral vector is intro- 
duced into a packaging cell line into 
which the structural genes (which lack a 
packaging signal) have previously been 
transfected (Danos and Mulligan 1988) 
(Figure 1). The structural genes, pro- 
vided in trans in the packaging cell, 
allow the production of a virus particle 
containing the foreign DNA. The viral 
particle can infect a host cell, the foreign 
DNA is inserted into a random site in the 
host genome, and the host cell can 
express the foreign gene. 
The simplest vectors contain a single 
gene. In this form, a single gene is ligated 
into the defective retroviral genome, and 
this gene is regulated by the long termi- 
nal repeat sequences in the native virus. 
Multiple gene vectors incorporate more 
than one (generally two) gene(s) into the 
viral backbone, each under regulation 
from separate promoters. Often, a se- 
lectable marker (that is, drug resistance 
gene) is introduced along with the for- 
eign gene so that relatively pure popula- 
tions of cells expressing the foreign gene 
can be isolated. 
Retroviruses and their vectors are 
thought to integrate almost entirely into 
random sites in the host cell genome. 
Random integration could potentially 
lead to insertional mutagenesis through 
the interruption of cellular genes or 
through the insertion of retroviral regu- 
latory sequences that modulate the ex- 
pression of cellular genes. In practice, 
this complication has not been reproduc- 
ibly observed. 
Another potential problem with the 
use of defective retroviral vectors is the 
appearance of wild-type virus in pro- 
ducer cells through the recombination 
between the transfected vector plasmid 
and endogenous retrovirus-like sequences. 
To reduce the possibilities for productive 
recombination, helper cell lines that 
express the gag, pol, and env genes have 
been produced from separate plasmids 
with independent selectable markers 
(Danos and Mulligan 1988). 
l Cardiovascular Diseases 
Because of the large number of people 
afflicted each year, cardiovascular dis- 
ease is an obvious and desirable target 
for gene transfer and gene transplanta- 
tion. Various cell types may be potential 
targets. Endothelial cells play an impor- 
tant role in the pathogenesis of athero- 
sclerosis and other vascular diseases, as 
they regulate hemostasis (Esmon 1987; 
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Figure 2. 8-Galactosidase activity in endothelial cells in vitro and in viva. Analysis of 
8-galactosidase expression in endothelial cells was performed by histochemical staining in (A) 
uninfected porcine endothelial cells; (B) endothelial cells infected with the BAG retmviral 
vector: (C) normal segment of control artery: (D) segment of artery instilled with BAG-infected 
endothelial cells; (E) microscopic cross-sectionof control artery; and(F) microscopic cross-section 
of artery instilled with BAG-infected endothelial cells. From Nabel et al. (1989). 
Rodgers 1988) and modulate smooth 
muscle cell growth and tone (Furchgott 
and Zawadzki 1980; Berk et al. 1986; 
Palmer et al. 1987). One approach to the 
treatment of local vascular disease would 
be to express genes at specific sites in the 
circulation that might ameliorate the 
process in situ. Because endothelial cells 
are found at diseased sites, they repre- 
sent potential carriers to convey thera- 
peutic agents, which might include anti- 
coagulant, vasodilatory, angiogenic, or 
growth inhibitor factors. Endothelial cell 
gene modification then could be a thera- 
peutic approach to the treatment of 
some vascular disorders. Alternatively, 
the myocardial cell is also a potential 
target for gene transfer, in order to 
promote angiogenesis in regions of in- 
jured myocardium or to correct inher- 
ited abnormalities of myocytes. Finally, 
the treatment of familial hypercholesterol- 
emia, which results from the genetic 
deficiency of low-density lipoprotein 
(LDL) receptors, may be amenable to 
gene therapy by targeting the LDL recep- 
tor gene into hepatocytes of hyper- 
cholesterolemic patients (Wilson et al. 
1988b). These cells represent potential 
targets for genetic modification that are 
in early phases of investigation. This 
field is rapidly evolving but has no 
immediate clinical application. 
l Retroviral Gene Transfer to the 
Endothelium and in vivo Expres- 
sion of Recombinant Genes 
In our initial experiments, we asked 
whether endothelial cells could be 
genetically modified in vitro and then 
implanted onto a local arterial seg- 
ment in vivo. Such a model system 
would provide an approach for the in 
vivo delivery of gene products to the 
vasculature (Nabel et al. 1989). To test 
these hypotheses, we first established 
a primary line of endothelial cells in 
tissue culture, which were derived 
from the Yucatan minipig, a naturally 
occurring atherosclerotic model. The 
endothelial cell identity of this line 
was confirmed by the presence of 
growth characteristics and morphol- 
ogy typical of porcine endothelium. 
The endothelial cells were infected in 
vitro with a retroviral vector express- 
ing the enzyme j3-galactosidase. This 
enzyme, which is present in Escher- 
ichia coli, was chosen as a marker 
because it is not normally present in 
mammals and stains blue with histo- 
chemical methods. The genetically mod- 
ified endothelium, now expressing the 
foreign gene P-galactosidase, was identi- 
fied in tissue culture by blue staining 
(Figure 2B) (Nabel et al. 1989). These 
modified endothelial cells also re- 
tained endothelial cell function dem- 
onstrated by analysis of LDL receptor 
uptake. Endothelial cells express re- 
ceptors for the acetylated form of LDL 
(AcLDL) in contrast to other mesenchy- 
ma1 cells (Pitas et al. 1983). Both 
infected and uninfected endothelial 
cells expressed AcLDL receptors, 
whereas fibroblast cells did not (Fig- 
ure 3). The genetically altered endo- 
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Figure 3. Acetylated low-density lipoprotein (AcLDL) receptor expression in normal and 
P-galactosidase expressing porcine endothelial cells. Endothelial cell cultures (left) were 
analyzed for the expression of the AcLDL receptor using a fluorescent-labeled AcLDL (right). 
(A) Normal porcine endothelial cells. (B and C) Two porcine endothelial cell lines infected 
with the BAG-transducing retroviral vector. (D) Fibroblast controls. From Nabel(1989). 
thelial cells were introduced into the 
iliofemoral artery of the Yucatan mini- 
pig by surgical exposure using a dou- 
ble balloon catheter (USCI, Bard, Bill- 
erica, MA) (Figure 4). Inflation of the 
proximal and distal balloons creates a 
central space that allows for the infu- 
sion of infected cells through an instil- 
lation port. A local region of the 
iliofemoral artery had been mechani- 
cally denuded of endothelium in order 
to allow adherence of genetically mod- 
ified endothelial cells. The infected 
cells were instilled into the central 
space for 30 min followed by removal 
of the catheter and restoration of 
antegrade blood flow. 
Two to four weeks later, the arterial 
segments inoculated with the 8- 
galactosidase expressing endothelium 
were removed and examined. Exami- 
nation of the gross sections of artery 
segment after histochemical staining 
revealed areas of blue coloration, indi- 
cating P-galactosidase expression (Fig- 
ure 2D) (Nabel et al. 1989). Under light 
microscopy, 8-galactosidase staining 
was observed in endothelial cells in the 
intima layer (Figure 2F) (Nabel et al. 
1989). Examination of control artery 
segments from sham-operated-upon 
minipigs revealed no evidence of p- 
galactosidase expression (Figure 2C 
and E) (Nabel et al. 1989). 
The introduction of genetically modi- 
fied endothelial cells into the vascular 
wall by catheterization is an initial 
step in the development of localized 
biochemical and pharmacologic treat- 
ment for vascular disease by using 
genetically altered endothelium as a 
vector. Endothelial cells may serve as 
a vehicle to introduce therapeutic pro- 
teins into diseased arterial segments. 
This technique may also potentially be 
used to treat other vascular diseases 
and to improve the performance of 
vascular grafts (Wilson et al. 1989) or 
stems (Dichek et al. 1989). 
Because endothelial cells line all 
blood vessels, they are an ideal target 
to direct gene products into the blood- 
stream to treat other systemic or 
inherited disorders. For example, the 
factor-VIII gene could be introduced 
into a population of endothelial cells 
(in a microcirculation) and the factor- 
VIII protein produced by the modified 
endothelium could in turn correct a 
hemophilia disorder. 
l Direct Gene Transfer into the 
Arterial Wall 
The previous studies established the 
feasibility of genetically altering endo- 
thelial cells in vitro and implanting them 
in vivo. However, it would be difficult to 
use this technique clinically, since it 
might take several weeks to genetically 
prepare a patient’s cells in vitro prior to 
in situ instillation. Rather, it would be 
advantageous to directly modify vascu- 
lar cells in vivo, for example, during 
Figure 4. Introduction of endothelial cells into the iliofemoral artery by catheterization. 
Double balloon catheter used for instillation of endothelial cells (top). Schematic representa- 
tion of catheter placement in the iliofemoral artery (bottom). From Nabel et al. (1989). 
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catheterization. 
We have performed further experi- 
ments to test the hypothesis that vascu- 
lar cells could be directly transduced in 
vivo. Using the same porcine model 
described above, the l%galactosidase ex- 
pressing retroviral vector was directly 
instilled into an iliofemoral artery seg- 
ment (Nabel et al. 1990). These arterial 
segments were infected by the retrovirus 
in vivo and expressed the recombinant 
P-galactosidase gene for at least 5 
months. We found that all three cell wall 
layers were infected including intima, 
media, and adventia. Further immu- 
nohistochemical studies demonstrated 
that endothelial and vascular smooth 
muscle cells were primarily infected. In 
addition to directly transferring genes 
into arterial ‘cells with a retrovirus, our 
subsequent experiments have demon- 
strated that DNA can also be transfected 
into vascular cells by using liposomes. 
This latter technique offers several ad- 
vantages over retroviruses, including 
safety and ease of preparation. 
To ensure that infection of the arterial 
segments with a replication-defective 
retrovirus is safe, we examined all pigs 
for the presence of helper virus, reverse 
transcriptase activity, and P-galactosi- 
dase activity in liver, lung, kidney and 
spleen. We found no evidence for retro- 
virus or P-galactosidase activity in these 
organs for up to S months. 
These studies demonstrate that direct 
gene transfer can be achieved in vivo by 
infection with a retroviral vector or 
transfection with liposomes and that the 
genetic modification is limited to the site 
of cell transduction. 
Before these techniques can be ap- 
plied to the treatment of human disease, 
several major concerns must be resolved. 
The level of expression of the foreign 
gene should be determined. The stability 
and longevity of gene expression must be 
understood. Promoters and enhancers 
that regulate gene expression need to be 
well characterized. Untoward cellular 
events resulting from overexpression of 
recombinant genes must be determined. 
Safety aspects need to be delineated and 
the risk to benefit ratio of introducing 
recombinant genes into host organisms 
must be defined. 
l Future Directions 
Gene transfer can be utilized to intro- 
duce foreign DNA into somatic cells in 
order to study and potentially treat ac- 
quired and inherited disorders. Retrovi- 
ral vectors may be used as delivery 
vehicles for the introduction of genes 
into host cells, provided that potential 
problems with recombination can be 
avoided. Alternative transfection meth- 
ods are under intensive investigation. 
Gene transfer technology is a powerful 
tool that can be used to study basic 
questions of vascular wall biology, such 
as cellular interactions and effects of 
growth promoting and growth inhib- 
itory factors. The techniques have poten- 
tial application to the treatment of many 
cardiovascular diseases, such as athero- 
sclerosis, and to the design of new drug 
delivery systems. 
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Analysis of Local Gene Expression 
in Human Atherosclerotic Plaques 
by in situ Hybridization 
Josiah N. Wilcox 
In situ hybridization is an invaluable tool for the examination of gene 
expression in human atherosclerotic plaques, and therefore is useful for 
research into the underlying mechanisms of atherogenesis. Information 
obtained using this technique includes determining not only the presence 
or absence of a specific mRNA in a tissue sample, but also the type of cell 
expressing the gene of interest. Cells containing platelet-derived growth 
factor (PDGF) mRNA were identified in carotid endarterectomy speci- 
mens by in situ hybridization. Mesenchymal-appearing intimal cells, the 
major cell type containing PDGF mRNAs and expressing PDGF, were 
often found associated with focal regions of organizing thrombus. It is 
suggested that organization of thrombi resulting from plaque rupture or 
intraplaque hemorrhage of the vasa vasorum may contribute to the 
episodic growth of the atherosclerotic plaque through an influence on 
these cells. 
Atherosclerotic lesions are heterogeneous fined mesenchymal-appearing cells. 
tissues containing a number of different Within the plaque there can be necrosis, 
cell types, including monocytes, macro- calcification, and focal areas of throm- 
phages, smooth muscle cells, T cells, bus organization that may originate 
endothelial cells, and a variety of unde- either from plaque rupture or intra- 
plaque hemorrhage resulting from dis- 
ruption of the vasa vasorum within the 
Josiah N. Wilcox is at the Division of Hema- intima. Little has been obtained con- 
tology/Oncology, Drawer AR, Emory Univer- ceming gene expression in human ath- 
sity School of Medicine, Atlanta, GA 30322. erosclerotic tissues, and much of our 
understanding of the cellular relation- 
ships in this disease comes from either in 
vitro experimentation or animal models. 
Unfortunately no animal model yet de- 
veloped completely recreates all of the 
important aspects of this disease. It is of 
paramount importance for us to under- 
stand what factors may be made locally 
in human plaques that might contribute 
to fat deposition, smooth muscle prolif- 
eration, inflammation, plaque rupture, 
or thrombosis. However, these are very 
difficult studies to do using conventional 
methods, which rely on tissue extracts 
(that is, Northern blots/Western blots) 
because of the heterogeneous nature of 
plaque tissue. The challenge is to analyze 
gene expression and protein content at 
the cellular level within developing pla- 
ques as well as old, clinically significant 
lesions. 
In an attempt to understand the pa- 
thophysiology of human atherosclerosis, 
studies have been conducted examining 
human atherosclerotic tissue by using 
the technique of in situ hybridization, a 
method for identifying mRNA at the 
cellular level. Like Northern blots, in situ 
hybridization depends on the hybridiza- 
tion of a radioactive nucleic acid probe 
(RNA or DNA) to a complementary 
sequence of mRNA. The two techniques 
differ in that the starting material for a 
Nor-them blot is a tissue digest, whereas 
the primary material for in situ hybridi- 
zation is a histologic tissue section. All of 
the cellular relationships are lost with 
Northern blots and RNA levels are aver- 
aged from all of the cells contained in the 
original sample. In situ hybridization is 
exquisitely sensitive and can detect the 
amount of mRNA contained in a single 
cell. Furthermore, since in situ hybridi- 
zation is a histologic technique, cellular 
relationships are maintained and it is 
possible to precisely identify cell types 
expressing the gene of interest. Thus, 
potentially important interactions be- 
tween cells that express different pro- 
teins may be uncovered. 
A major advantage of in situ hybridi- 
zation is that it enables the maximum 
use of limited tissues coming from human 
surgery. A tissue digest from a surgical 
biopsy of a carotid plaque might yield 
sufficient RNA for one or two Northern 
blots that, when hybridized, would only 
yield information regarding the presence 
or absence of a single mRNA species 
without any other information as to the 
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